Soligenix Highlighted in Audio Feature Emphasizing Urgent Need for Rare Disease Therapies

Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, is featured in a new NetworkNewsAudio APR titled "Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now." The feature highlights the growing impact of chronic and rare conditions on older adults, with more than 30 million Americans affected and most lacking FDA-approved therapies. This context places significant importance on the development of new treatments.

The company's lead candidate, HyBryte(TM) for cutaneous T-cell lymphoma (CTCL), is now in the final confirmatory trial needed before global marketing submissions. This progress is particularly timely as the administration advances new health policy initiatives related to chronic and rare diseases. The development represents a potential treatment option for a condition that currently has limited approved therapies.

Soligenix's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of CTCL. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, and first-in-class innate defense regulator technology for inflammatory diseases.

The company's Public Health Solutions business segment includes development programs for vaccine candidates, incorporating proprietary heat stabilization platform technology known as ThermoVax(R). This business segment has been supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases (NIAID), accessible at https://www.niaid.nih.gov, the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).

The NetworkNewsAudio feature and Soligenix's developmental progress come at a critical juncture for rare disease treatment in the United States. The combination of scientific advancement and evolving policy frameworks creates an environment where new therapies could reach patients more efficiently. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX, while the full press release can be viewed at https://ibn.fm/mnTOI. InvestorWire, which produced the feature, is a specialized communications platform within the Dynamic Brand Portfolio that provides advanced wire-grade press release syndication and can be accessed at https://www.InvestorWire.com.